RT Journal Article
SR Electronic
T1 Effects of apolipoprotein B on the lifespan and risks of major disease including type 2 diabetes: a Mendelian randomization analysis using outcomes in first-degree relatives
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20227801
DO 10.1101/2020.11.09.20227801
A1 Tom G Richardson
A1 Qin Wang
A1 Eleanor Sanderson
A1 Anubha Mahajan
A1 Mark I McCarthy
A1 Timothy M. Frayling
A1 Mika Ala-Korpela
A1 Allan Sniderman
A1 George Davey Smith
A1 Michael V Holmes
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20227801.abstract
AB Background Apolipoprotein B (apoB) is emerging as the lipoprotein entity that is critical for the role that lipoprotein lipids play in the aetiology of coronary heart disease (CHD). In this study, we explored effects of genetically-predicted apoB on endpoints in first-degree relatives.Methods Univariable Mendelian randomization (MR) used a weighted genetic instrument (229 SNPs) for apoB. For endpoints that apoB associated with at FDR <5%, multivariable MR analyses including genetic instruments for LDL-C and triglycerides. Estimates are inferred causal effects per 1-SD elevated lipoprotein trait (for apoB, 1-SD= 0.24 g/L). Replication of estimates for longevity and T2D was conducted using conventional two-sample MR using summary estimates from GWAS consortia.Findings Parents were less likely to be alive with 10.7 months of life lost in fathers (95%CI: 7.6, 13.9; FDR-adjusted P=4.0×10−10) and 5.8 months of life lost in mothers (95%CI: 3.0, 8.52; FDR-adjusted P=1.7×10−4) per 1-SD higher apoB in offspring. Effects strengthened to ∼2 yrs of life lost in multivariable MR and replicated in conventional two-sample MR (OR surviving to 90th centile: 0.38; 95%CI: 0.22, 0.65). Genetically-elevated apoB caused higher risks of heart disease in all first-degree relatives and higher risk of stroke in mothers.Findings in first-degree relatives were replicated in two-sample multivariable MR which identified apoB to increase (OR 2.32; 95%CI: 1.49, 3.61) and LDL-C lower (OR 0.34; 95%CI: 0.21, 0.54) risk of T2D.Interpretation Higher apoB shortens the lifespan, and increases risks of heart disease and stroke. T2D effects may represent injurious effects of dyslipidaemia to pancreatic islets.Evidence before this study Prior observational and Mendelian randomization studies have indicated that circulating concentrations of apoB are of critical importance to lipid-mediated atherogenesis, manifest as coronary heart disease.Added value of this study In this study, we explored the effects of genetically-predicted elevations in apoB on multiple endpoints occuring in first degree relatives including longevity and sought replication of findings using more conventional methods to exploit the statistical power from data available in large-scale GWAS consortia. We identified that apoB had a deleterious effect on longevity, shortening the lifespan by months to years. Furthermore, apoB caused higher risks of CHD and stroke in first degree relatives. Finally, apoB was identified to increase risk of T2D, in contradistinction to LDL-C which lowered risk of T2D, when employing multivairable MR methods.Implications of all the available evidence Our findings support apoB as being the major lipoprotein entity critical for CHD and stroke and extends this to identify higher apoB as negatively impacting longevity and increasing risk of T2D. These findings highlight the critical role of apoB in causing cardiometabolic disease, which collectively shortens the lifespan.Competing Interest StatementMVH has collaborated with Boehringer Ingelheim in research, and in adherence to the University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit staff policy, did not accept personal honoraria or other payments from pharmaceutical companies. TMF has consulted for Sanofi, Boerhinger-Ingelheim and has research support from GSK. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. MMcC has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, MMcC and AM are employees of Genentech, and holders of Roche stock. Funding StatementTGR is a UKRI Innovation Research Fellow (MR/S003886/1). QW is supported by a postdoctoral fellowship from Novo Nordisk Foundation (NNF17OC0027034). TMF has received funding from the Medical Research Council, MR/T002239/1 and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 875534. This Joint Undertaking support from the European Union Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition. MMcC was a Wellcome Investigator supported by Wellcome funding (098381, 106130, 203141, 212259). MAK is supported by a research grant from the Sigrid Juselius Foundation, Finland. MVH works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre. GDS works in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol MC_UU_00011/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Research Ethics Committee (REC; approval number: 11/NW/0382) and informed consent was collected from all participants enrolled in UKBB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will become available on publication (supplementary materials)